Kronos Bio to Present Research at Major Medical Conferences
Kronos Bio, Inc. (Nasdaq: KRON), a leader in cancer treatment, is preparing for an exciting lineup of conferences next month. These events underscore their commitment to advancing small molecule therapeutics that specifically target cancers associated with deregulated transcription. Participating in these conferences not only reflects their dedication to research and innovation but also aims to disseminate vital advancements to the global medical community.
Upcoming Conferences
H.C. Wainwright 26th Annual Global Investment Conference
This prestigious conference will take place from September 9 to 11, where Kronos Bio's President and CEO, Norbert Bischofberger, Ph.D., is scheduled to present on September 9 at 2:30 p.m. ET. This session offers a valuable opportunity for investors and stakeholders to understand the company's vision and its clinical progress.
American Association for Cancer Research Ovarian Cancer Research Symposium
On September 20-21, the symposium in Seattle will feature a presentation by Kronos Bio's Director of Translational Development, Luis Carvajal, Ph.D. He will showcase a poster detailing his team's research on KB-0742, an oral CDK9 inhibitor designed for treating recurrent ovarian cancer. The session will also include an author discussion, allowing attendees to engage directly with the researcher.
International Myeloma Society Annual Meeting
Kronos Bio will participate in the International Myeloma Society's 21st Annual Meeting in Rio de Janeiro from September 25 to 28. Collaborator Mariateresa Fulciniti, Ph.D., will deliver an oral presentation on the impact of p300 catalytic inhibition on the growth of multiple myeloma cells. This session is vital as it will shed light on new therapeutic strategies for managing this type of cancer.
Webcast and Research Availability
Kronos Bio is committed to transparency and engagement with its audience by offering a live audio webcast of the H.C. Wainwright presentation. This webcast will be accessible on the company’s website under the Investors & Media section and will be available for replay for 30 days following the event. Additionally, the research posters presented at these medical meetings will also be available on the Kronos Bio website, ensuring that stakeholders and interested individuals can review the latest scientific advancements from the company.
About Kronos Bio
Kronos Bio, Inc. is leading the way in cancer treatment by focusing on small molecule therapeutics that address transcriptional deregulation—an important feature of cancerous cells. The company utilizes a distinctive discovery engine aimed at unraveling complex transcription factor networks, which assists in identifying druggable cofactors essential for tumor-specific conditions. Among their notable developments, Istisociclib (KB-0742) offers a powerful approach to counteract MYC deregulation in solid tumors, while KB-9558 targets IRF4 dependence in multiple myeloma through p300 inhibition.
With its headquarters in San Mateo and a research facility in Cambridge, Kronos Bio is dedicated to fostering innovation in oncological therapies. They encourage all interested parties to learn more by visiting their website.
Frequently Asked Questions
What is Kronos Bio focused on?
Kronos Bio is dedicated to developing small molecule therapeutics for cancer treatment, particularly those related to deregulated transcription.
When is the H.C. Wainwright Conference?
The H.C. Wainwright 26th Annual Global Investment Conference is set for September 9-11, 2024.
Who will present at the AACR Symposium?
At the AACR Symposium, Luis Carvajal, Ph.D., will present a poster discussing the clinical expansion of KB-0742.
How can I access the webcast of the presentation?
The live audio webcast of the H.C. Wainwright presentation will be available on the Kronos Bio website and can be replayed for 30 days afterward.
Is Kronos Bio involved in research collaborations?
Yes, Kronos Bio collaborates with institutions like the Dana-Farber Cancer Institute to enhance their research capabilities and findings.